[28-20-am] Pharmacotherapy (Oncology, Personalized, and Others)

3:24 PM - 3:36 PM JST(6:24 AM - 6:36 AM UTC)

[28-20-pm11] Evaluation of time-to-onset and outcome of cardiac adverse events related to pembrolizumab using post-marketing surveillance in Japanese patients.

○Yuko Kanbayashi¹, Eren Tsuchiya², Tadashi Shimizu ³, Mayako Uchida⁴ (1. Osaka Med. Pharm. Univ., 2. Doshisha Women’s Coll. Liberal Arts, 3. Sch. Pharm., Hyogo Med. Univ., 4. Dept. Pharm., Kyushu Univ. Hosp.)